Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored BRAF D594G and was wildtype for KRAS, NRAS and PI… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 350 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy who had individual response data and whose tumors were K… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 30 patients harbored BRAF V600E, were KRAS, NRAS and PIK3CA wt, a… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic colorectal cancer had a tumor which harbored BRAF V600E, was wildtype for NRAS, KRAS and PIK3CA, an… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 146 mutant tumors (n=11) … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 22 patients harbored KRAS G12A, were BRAF, NRAS and PIK3CA wt, and had individual response… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12C, were BRAF, NRAS and PIK3CA wt, an… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 76 patients harbored KRAS G12D, were BRAF, NRAS and PIK3CA wt, and had individual response… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12D, was wildtype for NRAS… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Chemotherapy-refractory patients with metastatic colorectal cancer harboring KRAS mutations (primarily G12/G13; n=230 out of 253 total KRAS mutant patients) had lower response rates (17/253; 6.7% vs K… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G12R, were wildtype for NRAS, BRAF and PIK… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored KRAS G12S, were BRAF, NRAS and PIK3CA wt, an… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 39 patients harbored KRAS G12V, were BRAF, NRAS and PIK3CA wt, and had individual response… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had a tumor which harbored KRAS G12V, was wildtype for NRAS… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 50 patients harbored KRAS G13D, were BRAF, NRAS and PIK3CA wt, and had individual response… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Three patients participating in a large retrospective study of EGFR monoclonal antibodies in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS G13D, were wildtype for N… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS mutant tumors (total [n = 253], codo… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients harboring KRAS codon 61 mutations (n=13) had a… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Seven patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61H (either c.183A > C or >T) and were wi… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61K. One patient was a 61 year old female w… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61L. One patient, a 67 year old male, whose… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored KRAS Q61R and were wild type for PIK3CA, BRAF, an… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, an… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS wildtype, NRAS assessable tumors, an… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61, N=13) was not informative for disease control rate, progression free survival or overall survival follo… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Chemotherapy-refractory patients with KRAS wt metastatic colorectal cancer harboring NRAS mutation (primarily Q61, n=10) have a significantly lower response rate to cetuximab than patients wildtype fo… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In a retrospective study of 368 chemotherapy-refractory metastatic colorectal cancer, patients with a NRAS mutation (n=13) treated with cetuximab in combination with standard chemotherapy were associa… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA.… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In chemotherapy-resistant colorectal cancer patients treated with cetuximab-based therapy, NRAS mutations were associated with a lower objective response (7.7% vs. 38.1%, odds ratio (OR):0.14, 95% CI:… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In chemotherapy-resistant colorectal cancer patients treated with cetuximab-based therapy, NRAS mutations were associated with a lower objective response (7.7% vs. 38.1%, odds ratio (OR):0.14, 95% CI:… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Four patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61K and were wildtype for KRAS, BRAF and P… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PI… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and P… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA C420R and was wildtype for KRAS, BRAF and … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic colorectal cancer. Of those, 7 patients harbored PIK3CA E542K (exon 10), were wt for BRAF, NRAS and PIK3CA, and had ind… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 691 cetuximab treated patients with metastatic, chemotherapy refractory colorectal cancer. Of those, 16 patients harbored PIK3CA E545K (exon 10), were wt for BRAF, NR… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E545Q (exon 10), were wildtype for NRAS, B… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA E81K, were wildtype for NRAS, BRAF and PIK… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

In chemotherapy-refractory patients with metastatic colorectal cancer and KRAS wt tumors, Exon 10 PIK3CA mutations (listed as Exon 9 in the source) had no significant impact on response rate (6/21 [28… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Chemotherapy-refractory patients with metastatic colorectal cancer harboring wildtype KRAS and Exon 21 (listed as exon 20 in the source) PIK3CA mutations had lower response rates (0/9 vs 121/329; OR: … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA G1049R (exon 20), was wildtype for KRAS, B… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047L (exon 21), were wildtype for NRAS, … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA H1047R (exon 21), were wildtype for KRAS,… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

This was a retrospective study of 605 patients with metastatic, chemotherapy refractory colorectal cancer treated with cetuximab + chemotherapy. Patients with KRAS wildtype, PIK3CA assessable tumors, … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

Three patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored PIK3CA N345K, were wildtype for KRAS, BRAF and … (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA Q546K (exon 10), was wildtype for KRAS, BR… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC

One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored PIK3CA R88Q, was wildtype for KRAS, BRAF and NRAS… (full text at CIViC)

PMID 20619739 · De Roock et al., 2010 · Open in CIViC